National Bank of Canada FI Has $66.98 Million Position in Danaher Co. (NYSE:DHR)

National Bank of Canada FI trimmed its stake in Danaher Co. (NYSE:DHR) by 46.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 274,111 shares of the conglomerate’s stock after selling 234,204 shares during the quarter. National Bank of Canada FI’s holdings in Danaher were worth $66,975,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in DHR. Norges Bank acquired a new position in Danaher during the 4th quarter worth approximately $1,752,382,000. Vanguard Group Inc. raised its position in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares in the last quarter. Swedbank AB acquired a new stake in Danaher in the 1st quarter valued at $676,545,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in Danaher by 214.4% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after purchasing an additional 2,096,038 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last ninety days. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Performance

Shares of DHR stock opened at $264.80 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market cap of $196.13 billion, a price-to-earnings ratio of 44.88, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The firm’s 50-day simple moving average is $260.98 and its two-hundred day simple moving average is $255.61.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the firm posted $2.05 EPS. Danaher’s revenue was down 2.9% on a year-over-year basis. As a group, equities analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DHR shares. The Goldman Sachs Group raised their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen lifted their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Bank of America lifted their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, Royal Bank of Canada increased their price target on Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.